Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma

Autor: Masatoshi Ishigami, Teiji Kuzuya, Yoji Ishizu, Takashi Honda, Mitsuhiro Fujishiro, Tetsuya Ishikawa, Takanori Ito
Rok vydání: 2020
Předmět:
Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Carcinoma
Hepatocellular
Drug-Related Side Effects and Adverse Reactions
Kaplan-Meier Estimate
Antibodies
Monoclonal
Humanized
Disease-Free Survival
Ramucirumab
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Albumins
Internal medicine
Humans
Medicine
Adverse effect
Aged
Neoplasm Staging
Retrospective Studies
Aged
80 and over
business.industry
Phenylurea Compounds
Incidence (epidemiology)
Liver Neoplasms
Bilirubin
Retrospective cohort study
General Medicine
Middle Aged
medicine.disease
digestive system diseases
chemistry
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Quinolines
Female
alpha-Fetoproteins
business
Lenvatinib
Alpha-fetoprotein
Zdroj: Anticancer Research. 40:2089-2093
ISSN: 1791-7530
0250-7005
Popis: Background/aim The outcomes of ramucirumab after lenvatinib failure for hepatocellular carcinoma (HCC) patients with alpha fetoprotein (AFP) levels of ≥400 ng/ml are unknown. Patients and methods Of 12 patients treated with ramucirumab after lenvatinib failure, 10 patients were enrolled in this retrospective study. Results The disease control rate of 80% at 6 weeks and the median time to progression of 3.1 months were the same by both the Response Evaluation Criteria in Solid Tumors (RECIST) and the modified RECIST. AFP reduction was seen in 5 patients at 2 weeks and in 3 patients at 6 weeks. The incidence of grade 3 adverse events was low at 10%. The albumin-bilirubin scores within 6 weeks did not worsen. Conclusion Ramucirumab might have potential therapeutic efficacy and safety in advanced HCC patients after lenvatinib failure. Further studies are needed to confirm the outcomes of ramucirumab after lenvatinib failure.
Databáze: OpenAIRE
Externí odkaz: